Profile: Aerie Pharmaceuticals Inc (AERI.OQ)
Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.
The Company's product, Rhopressa, is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. By inhibiting these targets, Rhopressa reduces IOP through the mechanisms of action (MOAs), including through ROCK inhibition, it increases fluid outflow through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the eye; also through ROCK inhibition, it reduces episcleral venous pressure (EVP), which represents the pressure of the blood in the episcleral veins of the eye where eye fluid drains into the bloodstream, and through NET inhibition, it may potentially reduce the production of eye fluid.
The Company's second product candidate, Roclatan, is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
The Company competes with Valeant Pharmaceuticals International, Inc., Novartis International AG, Allergan, Inc. and Santen Inc.
Aerie Pharmaceuticals Inc
4301 Emperor Blvd Ste 400
DURHAM NC 27703-7615